Stoney.... the real King of GBA could do like you did on RIVN and lose it all. It's halted. When was the last time this happened? That biotech you bet the farm on and lost 90%. $11 down to $1. Well the good news is... thank god.... at least I didn't recommend buying the stock to the readers. VZ stayed mum... wisdom... analyzing a dozen things before he jumped in. NOW IT'S HALTED. In your own words.... allow me to procure them for my own in light of this... If this thing drops to zero.... Van resigns from GBA with a well-deserved severance package and goes home. "You have been warned" <------- EDIT: CHILDREN.... THIS IS WHAT HAPPENS WHEN THE THREAD STARTER HARVESTS IDEAS SOLELY FROM FREE WEBSITES. He may get lucky on this one though... VZ's proprietary scanners flagged it. If he does... my option gift to ya'll will be a two bagger.
The Good news is my scanners flagged both options and volume over a 3 day period. The bad news is that works with regular stocks.... but biotechs.... not so much. But we'll see. Obviously Stoney gave us no DD on this one, but I liked it at first glance and entered it into the window. Lets hope I was right.
UH-OH.... I found Stoney's source... As a general rule of thumb.... Simply Wall Street.... if you don't pay for the premium membership... the free for retail traders is garbage. And here ya go: October 13, 2023 at 9:16 AM·4 min read In this article: ARDX Key Insights Institutions' substantial holdings in Ardelyx implies that they have significant influence over the company's share price The top 23 shareholders own 50% of the company Recent sales by insiders A look at the shareholders of Ardelyx, Inc. (NASDAQ:ARDX) can tell us which group is most powerful. The group holding the most number of shares in the company, around 59% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 19% in value last week. However, the 137% one-year return to shareholders may have helped lessen their pain. We would assume however, that they would be on the lookout for weakness in the future. Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Ardelyx already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Ardelyx's earnings history below. Of course, the future is what really matters. earnings-and-revenue-growthearnings-and-revenue-growth earnings-and-revenue-growth Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in Ardelyx. Our data shows that State Street Global Advisors, Inc. is the largest shareholder with 10% of shares outstanding. In comparison, the second and third largest shareholders hold about 10% and 6.4% of the stock. __________________________________________________________________ Now, with all that said.... my scanner doesn't flag dogs.... so.... this one may be a a big winner. Or it goes to zero.
original idea? Check the dates and prose. ---> You should spell it out for us Stoney. It's "Simply Wall Street" Van.
Ok Stoney.... now you can end the thread. Ardelyx wins long battle for FDA approval of kidney-disease treatment By Eleanor Laise Drug previously rejected by regulators gets green light and is set to launch later this year Ardelyx Inc. (ARDX) on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease. The biopharma company said late Tuesday that the U.S. Food and Drug Administration on Tuesday approved tenapanor, marketed under the brand name Xphozah, for control of serum phosphorus in patients with chronic kidney disease on dialysis. A high level of phosphorus in the blood is often a sign of kidney damage and can lead to weak bones, joint pain, cardiovascular problems and other issues. The approval concludes an extraordinary comeback for Xphozah. Ardelyx's application for approval of the treatment was previously rejected by the FDA in July 2021, when the agency said the drug's effect was "small and of unclear clinical significance." To preserve cash, Ardelyx a few months later said it would cut its workforce by 65%, but it also pursued multiple appeals of the agency's decision. An FDA advisory committee voted last November that the benefits of Xphozah outweigh its risks. The agency late last year ultimately granted Ardelyx's appeal, and the company resubmitted its Xphozah application to the FDA in April. More than 550,000 people in the U.S. have chronic kidney disease and are on maintenance dialysis. The vast majority of them have high phosphorus levels, also called hyperphosphatemia, according to Ardelyx. High phosphorus levels "must be taken care of in these patients, and the current therapies are mostly insufficient in doing so," Ardelyx CEO Mike Raab told MarketWatch. Chronic kidney disease patients with high phosphorus levels have traditionally been treated with phosphate binders that can soak up phosphorus from food during digestion, but that approach can require patients to swallow a large number of pills. The Xphozah treatment requires two pills a day, "each the size of a Tic Tac," Raab said. The FDA approved Xphozah as add-on therapy in patients who can't tolerate or have an inadequate response to phosphate binders, Ardelyx said in a release. Xphozah, which will be Ardelyx's second U.S. product launch, should be available sometime in November, Raab said. Ardelyx will present updated data on Xphozah for hyperphosphatemia at an American Society of Nephrology meeting in early November, the company said in a release Monday. Ardelyx shares jumped in late September after Japanese regulators approved tenapanor for hyperphosphatemia in adults with chronic kidney disease on dialysis. Ardelyx shares fell 0.6% on Tuesday and have gained 21% in the year to date, while the S&P 500 SPX has gained 13.9%. (END) Dow Jones Newswires
Kind of the gummy that won't die-- Trying to wrap up al of these trades.//// Ardelyx price target raised to $10 from $8.50 at Ladenburg » 06:56 ARDX
Does anyone know has the FAA signed off on this?/ If you buy one you can actually fly? Lilium Jet Becomes First eVTOL for Private Sale in the U.S. in Pioneering Partnership with EMCJET- Lilium has opened private sales of its eVTOL jets in the U.S. market Lilium Pioneer Edition Jet flying over Dallas Texas-based EMCJET, responding to premium market interest, secures production slots for the first U.S. Lilium Pioneer Edition Jets Marks the first time Lilium Jets, or any eVTOL aircraft, will be available for private purchase in the U.S. market Initial sales focus will be on customers in key Texas cities including Austin, Houston, San Antonio, and Dallas HOUSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Lilium N.V. (NASDAQ: LILM), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, has today opened private sales of its eVTOL jets in the U.S. market, in partnership with EMCJET, an industry-leading full-service aircraft brokerage and management company. EMCJET is set to be the exclusive Lilium dealer in Texas through 2030 for private sales. Under the terms of the partnership, which includes a commercial commitment to Lilium for five production slots, EMCJET will enable individuals to purchase some of the first Lilium Pioneer Edition Jets available in the U.S. market. This announcement is the first step in unlocking the U.S. private aviation market, the largest private aviation market, for Lilium and follows Lilium’s commercial strategy to start in the premium market before expanding to the airline and passenger shuttle market. EMCJET, renowned for its expertise in international aircraft trading and services, is dedicated to offering customers a seamless and sophisticated experience when it comes to buying, selling, and acquiring aircraft. The Lilium Jet will be available countrywide, with the initial focus on key cities in Texas, including Austin, Houston, San Antonio, and Dallas, aligning with Texas' commitment to sustainability, delivering efficient and eco-friendly transportation choices for residents and visitors. “We are thrilled to partner with EMCJET as we embark on our mission to revolutionize regional air mobility in the United States. EMCJET’s proven track record of private premium market jet sales in the U.S. and managing privately owned aircraft and exceptional customer service aligns seamlessly with Lilium's vision of delivering an unparalleled flying experience to our potential customers,” said Sebastien Borel, Chief Commercial Officer at Lilium. The Lilium Pioneer Edition Jet is Lilium’s planned first edition version of the Lilium Jet being sold to private individuals across the globe. The Lilium Jet is an all-electric vertical take-off and landing jet, designed to offer leading capacity, low noise, and high performance with zero operating emissions purpose-built for regional connectivity. “EMCJET is excited to be at the forefront of introducing Lilium's groundbreaking eVTOL technology to the Texas and U.S. markets,” said Memo Montemayor, Founder & CEO of EMCJET. “Our client-first mentality ensures that we deliver superior value and expert attention required in making sound private aviation investments and introducing our clients to the most innovative modern technology for current and future market practices. This partnership with Lilium will allow us to serve our well-established network of aviation enthusiasts with the latest technological advancements and continue to provide exceptional service and results that our clients deserve and depend on.” The agreement with EMCJET marks Lilium’s fourth dealer globally. “Dealers and aircraft management companies are eager to partner with Lilium on jet sales to help decarbonize general aviation and provide an elevated flying experience, all while being incredibly efficient to operate,” added Borel. Lilium GmbH
Gimme some Joyburst. Flow Beverage signs 45 million unit co-pack agreement with Joyburst Oct. 18, 2023 7:33 AM ET Flow Beverage Corp. (FLWBF), FLOW:CA Flow Beverage (OTCQX:FLWBF) Wednesday said it has entered into a three year manufacturing agreement with Joyburst Beverages, having guaranteed annual production of 15 million Joyburst Hydration branded beverage units, which will be produced in Flow’s Aurora, Ontario production facility. This manufacturing agreement helps Flow unlock value in relation to its Aurora production facility which, as previously disclosed, is currently in the process of being divested, -? said Nicholas Reichenbach, Chief Executive Officer of Flow.